
Pharmacally
Disease & Drugs
Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.
Latest in Disease & Drugs
New Drug ApprovalBayer Wins China Approval for Sevabertinib After 75% Response RateBayer has secured NMPA approval in China for sevabertinib as a first-line treatment for advanced HER2-mutant NSCLC.Fact-Checked
Clinical TrialsSanofi Terminates Nurix’s Oral STAT6 Degrader ProgrammeSanofi has terminated the Phase 1 clinical trial and development programme for Nurix’s oral STAT6 degrader SAR448272.Fact-Checked
Clinical TrialsPfizer Ends Development of Three Candidates in ITP, PAH and ObesityPfizer has discontinued three investigational drug programmes targeting ITP, pulmonary arterial hypertension and obesity.Fact-Checked
Clinical TrialsHoth Ends HT-001 Phase 2a Early, Plans FDA Talks on Potential Phase 3Hoth Therapeutics has concluded its Phase 2a trial of HT-001 ahead of schedule following positive interim efficacy findings.Fact-Checked
Clinical TrialsSeres Reports 77% Reduction in Bloodstream Infections With SER-155Seres Therapeutics’ investigational live biotherapeutic SER-155 was associated with a 77% relative reduction in bloodstream infections among allogeneic stem cell transplant recipients in a Phase 1b study.Fact-Checked
Clinical TrialsMerck Advances Ohtuvayre into Phase 3 COPD Exacerbation TrialMerck has initiated the Phase 3 ENHANCE-3 trial to evaluate whether Ohtuvayre (ensifentrine), added to standard-of-care therapy, can reduce moderate or severe COPD exacerbations.Fact-Checked
Clinical TrialsTiziana Reports Positive Phase 2a Results for Intranasal ForalumabTiziana Life Sciences reported positive Phase 2a INFORM-MS results for intranasal foralumab in non-active secondary progressive multiple sclerosis.Fact-Checked
Clinical TrialsGSK Depemokimab Maintains Asthma Control Over Two YearsGSK’s twice-yearly depemokimab maintained reductions in asthma exacerbations, improvements in symptom control and suppression of blood eosinophils over two years.Fact-Checked
Clinical TrialsIncyte Reports Positive Results for Povorcitinib in Vitiligo TrialsIncyte’s povorcitinib met the primary endpoint in both Phase 3 STOP-V1 and STOP-V2 trials in nonsegmental vitiligo.Fact-Checked
Clinical TrialsAgenus Reports 36% Major Response With BOT+BAL in Colon CancerAgenus’ Phase 2 UNICORN trial demonstrated a 36% major pathological response rate and 29% pathological complete response rate with neoadjuvant botensilimab plus balstilimab in pMMR/MSS colon cancer.Fact-Checked
Clinical TrialsTeva to Stop TOPAS-MSA Trial After Interim Futility FindingTeva Pharmaceuticals will discontinue its Phase 2 TOPAS-MSA trial evaluating emrusolmin in multiple system atrophy after an independent monitoring committee recommended stopping the study following a prespecified interim…Fact-Checked
Clinical TrialsMilestone Reports 66.7% PSVT Conversion With CARDAMYST After AblationMilestone Pharmaceuticals reported Phase 3 RAPID subgroup findings showing that CARDAMYST (etripamil) nasal spray converted recurrent paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm within 30 minutes in four…Fact-Checked
Explore more
Health TidingsIndustry, pipeline and company news.
RegulatoryApprovals, policy and agency decisions.
ResearchPeer-reviewed studies and scientific breakthroughs.
Drug FinderLook up any drug: uses, dosing and safety.
From the HistoryLandmark moments in pharmaceutical history.
LatestEvery new story, as soon as it is published.